- Report
- December 2024
- 332 Pages
Global
From €3820EUR$4,197USD£3,275GBP
- Drug Pipelines
- March 2025
- 450 Pages
Global
From €4551EUR$5,000USD£3,901GBP
- Report
- June 2024
- 200 Pages
Global
From €7235EUR$7,950USD£6,203GBP
- Drug Pipelines
- July 2020
- 33 Pages
Global
From €3185EUR$3,500USD£2,731GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €2730EUR$3,000USD£2,341GBP
- Clinical Trials
- January 2024
- 90 Pages
Global
From €2275EUR$2,500USD£1,951GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1138EUR$1,250USD£975GBP
- Report
- May 2023
- 220 Pages
Global
From €2275EUR$2,500USD£1,951GBP
- Report
- April 2023
- 350 Pages
Global
From €2958EUR$3,250USD£2,536GBP
- Report
- April 2023
- 500 Pages
Global
From €2958EUR$3,250USD£2,536GBP
- Report
- June 2023
- 126 Pages
Global
From €3276EUR$3,600USD£2,809GBP
- Report
- May 2022
- 58 Pages
Global
From €2275EUR$2,500USD£1,951GBP

CD28 is a type of oncology drug that works by blocking the activity of a protein called CD28, which is found on the surface of certain types of cancer cells. This protein is involved in the growth and spread of cancer cells, and blocking its activity can help to slow down the progression of the disease. CD28 drugs are used in combination with other treatments, such as chemotherapy and radiation therapy, to help improve the effectiveness of these treatments. They are also used to reduce the side effects of these treatments, such as nausea and fatigue.
CD28 drugs are used to treat a variety of different types of cancer, including breast, lung, and colorectal cancer. They are also used to treat some types of leukemia and lymphoma. CD28 drugs are generally well tolerated and have few side effects.
Companies in the CD28 market include Novartis, Merck, Pfizer, and AstraZeneca. These companies are involved in the research, development, and marketing of CD28 drugs. They are also involved in the production and distribution of these drugs to healthcare providers and patients. Show Less Read more